We serve Chemical Name:2,3-Dichlorothiobenzamide CAS:84863-83-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,3-Dichlorothiobenzamide
CAS.NO:84863-83-2
Synonyms:2,3-dichlorobenzenecarbothioamide;MFCD00221163
Molecular Formula:C7H5Cl2NS
Molecular Weight:206.09200
HS Code:2930909090
Physical and Chemical Properties:
Melting point:123-126°C
Boiling point:327.7ºC at 760 mmHg
Density:1.473g/cm3
Index of Refraction:1.669
PSA:58.11000
Exact Mass:204.95200
LogP:3.32790
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN2811
Packing Group:III
Contact us for information like 2,3-dichlorobenzenecarbothioamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00221163 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00221163 Use and application,MFCD00221163 technical grade,usp/ep/jp grade.
Related News: Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients. 2,3-Dichlorothiobenzamide manufacturer Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs. 2,3-Dichlorothiobenzamide supplier As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2,3-Dichlorothiobenzamide vendor Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients. 2,3-Dichlorothiobenzamide factory China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.
